News >

Novartis to Add Lutathera to Portfolio in Planned $3.9-Billion Deal

Jason Harris
Published: Monday, Oct 30, 2017

Bruno Strigini

Bruno Strigini
Novartis has announced a planned .9-billion acquisition of Advanced Accelerator Applications (AAA), a radiopharmaceutical company that develops, produces, and commercializes Molecular Nuclear Medicines.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication